Study at a glance
How does the body make and remove active vitamin D?
This page brings together laboratory studies of enzymes, animal experiments, human genetic disorders and evidence about hormone control. It explains two enzymes, proteins that help chemical reactions occur. CYP27B1 makes active vitamin D. CYP24A1 helps process forms of vitamin D so that their availability and effects are reduced over time. This is a review of several evidence types, not one trial.
What do the two vitamin D enzymes do?
CYP27B1 changes 25-hydroxyvitamin D into calcitriol, the main active vitamin D hormone. CYP24A1 processes both the earlier form and calcitriol through several chemical steps. Hormones help coordinate production and removal. Parathyroid hormone usually promotes activation in the kidneys, while FGF23 and calcitriol itself favour less active vitamin D being available.
What happens when vitamin D activation or removal fails?
Severe loss of CYP27B1 can prevent enough active vitamin D being made even when the earlier form is available. Loss of CYP24A1 creates the opposite problem: forms of vitamin D are not removed normally. In mice completely lacking CYP24A1, the time for blood calcitriol to fall by half increased from about 6 to 60 hours. That result describes a complete genetic loss in mice, not ordinary human variation.
Does vitamin D processing always make it inactive straight away?
Results from different species and experiments must be interpreted separately. Finding an activating enzyme outside the kidneys does not prove that the tissue supplies much active vitamin D to the blood. CYP24A1 is important but is not the only processing route. Its first chemical step also does not make every product immediately inactive; some possible effects of later products remain uncertain.
Read the full article below ↓CYP27B1 and CYP24A1 sit on opposite sides of the same physiological problem: how much active vitamin D should be produced, and how long should vitamin D metabolites remain available before they are further metabolised? The review by Jones, Prosser and Kaufmann brings together biochemical, structural, genetic and physiological evidence showing that CYP27B1 performs the defining 1α-hydroxylation step that forms calcitriol, while CYP24A1 initiates major pathways that progressively metabolise both 25-hydroxyvitamin D and calcitriol. Understanding the pair together is more useful than treating either enzyme as an isolated switch, because vitamin D activity depends on the balance between formation, local use, feedback and removal.
Why these two enzymes matter together
The Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1) overview places these reactions within the wider vitamin D pathway. Vitamin D metabolism is a sequence of enzyme-controlled transformations. The first major hydroxylation produces 25-hydroxyvitamin D [25(OH)D], the principal circulating indicator of vitamin D status. A second hydroxylation at the 1α position produces 1,25-dihydroxyvitamin D [1,25(OH)2D, or calcitriol], the high-affinity hormonal ligand for the vitamin D receptor. CYP27B1 performs that second activation step.
CYP24A1 then acts on both sides of the active-hormone pool. It can metabolise 25(OH)D before activation, reducing the amount of substrate available to CYP27B1, and it can metabolise calcitriol after activation, limiting the duration of active-hormone exposure. The physiological balance therefore depends not only on how much precursor is present, but on the relative rates at which precursor is activated and active or precursor metabolites are catabolised.
The review is particularly useful because it combines several kinds of evidence. Enzyme-expression and biochemical studies identify what the proteins can do; genetic disease and knockout models show what happens when the reactions are lost; structural and mutagenesis studies explain how CYP24A1 selects different oxidation routes; and endocrine physiology shows how the two enzymes are regulated in opposing directions.
CYP27B1 performs the decisive 1α-hydroxylation step
Several cytochrome P450 enzymes can contribute to the earlier 25-hydroxylation of vitamin D, which is why the first activation step has more enzymatic redundancy. The second step is much more specific. CYP27B1 is the established 25-hydroxyvitamin D 1α-hydroxylase responsible for converting 25(OH)D to calcitriol.
That conclusion is supported by more than enzyme assays. Human CYP27B1 loss-of-function mutations cause vitamin-D-dependent rickets type 1A, in which 25(OH)D can be present but calcitriol formation is inadequate. Knockout models similarly show loss of normal 1α-hydroxylated vitamin D metabolism and the expected disturbances of mineral homeostasis and skeletal development. These observations show why precursor concentration and active-hormone production are not interchangeable concepts: sufficient substrate cannot compensate for severe failure of the activating enzyme itself.
CYP27B1 can act on both vitamin D3: and vitamin D2-derived 25-hydroxylated substrates. Its catalytic activity takes place within mitochondria, so the enzyme does not work alone. Electrons derived from NADPH are transferred through mitochondrial redox partners, including ferredoxin reductase and ferredoxin, before reaching the P450 haem centre. That electron-transfer requirement matters because enzyme abundance is only one part of catalytic capacity; substrate access, mitochondrial environment and redox support are also part of the reaction system. Vitamin D Metabolism at the Cellular Level develops this intracellular handling in greater detail.
The kidney supplies the endocrine pool, while extra-renal CYP27B1 often serves local signalling
Renal CYP27B1 has a special physiological role because the kidney is the principal regulated source of circulating calcitriol under ordinary mineral-homeostatic conditions. In the proximal tubule, CYP27B1 sits inside a hormone-sensitive system that responds to PTH, phosphate, calcium, FGF23 and calcitriol itself. Changes in renal enzyme activity can therefore alter the endocrine supply of active vitamin D to the body.
The same CYP27B1 enzyme is also expressed outside the kidney. Evidence reviewed from tissues and cells including placenta, skin-associated cells, bone-related cells and macrophages established that extra-renal calcitriol synthesis does not require a separate 1α-hydroxylase. The important distinction is physiological scale rather than enzyme identity. Extra-renal CYP27B1 often supports local intracrine or paracrine signalling, so the calcitriol produced may primarily affect the tissue in which it is formed rather than making a major contribution to the circulating pool.
That distinction helps prevent a common overgeneralisation. Detecting CYP27B1 expression in a tissue shows that local activation is possible; it does not by itself show that the tissue is a major endocrine source of circulating calcitriol. Tissue-Specific Vitamin D Metabolism develops this renal-versus-local distinction across tissues.
CYP24A1 can metabolise both precursor and active hormone
CYP24A1 is also a mitochondrial cytochrome P450, but its physiological direction is opposite to CYP27B1. It initiates oxidative metabolism of 25(OH)D and calcitriol. This allows the enzyme to regulate vitamin D exposure at two points: it can divert precursor away from later activation and it can reduce the persistence of calcitriol after the hormone has formed.
Calling CYP24A1 simply the “24-hydroxylase” is useful shorthand but incomplete. Human CYP24A1 can initiate oxidation at carbon 24 or carbon 23 of the vitamin D side chain. Those first reactions are followed by further enzyme-catalysed oxidations, so the pathway is progressive rather than a single irreversible step.
The C24 route can proceed through successive side-chain oxidation products toward calcitroic acid. The C23 route can lead toward 26,23-lactone products. The existence of these parallel routes means that CYP24A1 determines not only whether a vitamin D metabolite is further processed, but also which family of downstream products is formed.
CYP24A1 is a processive enzyme, not an instantaneous molecular off switch
The multistep nature of CYP24A1 metabolism changes how its biological role should be described. The pathway generally reduces the availability and signalling duration of active vitamin D and promotes progression toward metabolites that can be eliminated. Vitamin D Clearance and Degradation develops the downstream chemistry and physiology of that removal. But it is too crude to say that the first CYP24A1 reaction makes every molecule biologically irrelevant immediately.
The review discusses evidence suggesting that some hydroxylated metabolites can retain biological activity, and it considers unresolved proposals that particular CYP24A1-derived products might have effects of their own. These observations do not overturn the enzyme’s dominant catabolic role. They do, however, mean that “catabolism” should be understood as progressive metabolic inactivation and clearance rather than a single all-or-none chemical event.
This is also why enzyme pathway terminology matters. CYP27B1 produces the principal active hormone, while CYP24A1 shifts vitamin D metabolites through routes that generally reduce hormonal exposure and facilitate removal. The two roles are opposite in physiological direction without being mirror-image one-step reactions.
Active-site structure controls whether CYP24A1 favours C24 or C23 oxidation
Structural and mutagenesis evidence gives a molecular explanation for CYP24A1 regioselectivity. The P450 protein folds around a haem-containing catalytic centre, while the shape of the substrate-binding cavity determines how the vitamin D side chain is positioned relative to the reactive oxygen species at the haem.
A striking comparison involved residues that differ between rat and human CYP24A1. Wild-type rat CYP24A1 strongly favoured C24 oxidation, with a reported C24:C23 product ratio of roughly 100:1. Substituting Thr416 with methionine reduced that ratio to about 12.5:1, while substituting Ile500 with threonine reduced it to about 6.3:1. Wild-type human CYP24A1 in the cited experimental series showed a ratio of about 3.7:1.
Those shifts are important because they demonstrate causality at the level of enzyme structure: changing individual amino acids substantially redirects the route taken by the same substrate. The substitutions did not completely reproduce the human enzyme’s product distribution, which implies that additional sequence differences also contribute. Cross-species work discussed in the review identifies residue 326 as another important determinant of C23-versus-C24 orientation.
The broader lesson is that expression level alone does not fully predict metabolite pattern. Enzyme sequence and substrate orientation can influence which downstream products are generated even when the same general CYP24A1 pathway is present.
Complete CYP24A1 loss shows how strongly the pathway controls calcitriol persistence
Knockout models provide a direct physiological test of CYP24A1’s contribution to hormone clearance. In Cyp24a1-null mice, the plasma half-life of calcitriol increased from roughly 6 hours to roughly 60 hours. A tenfold change of that size is much more informative than simply saying that clearance became slower. It shows that, under complete loss-of-function conditions, CYP24A1 can be a major determinant of how long calcitriol remains in circulation.
The knockout phenotype also generated an important interpretive complication. Skeletal abnormalities initially raised the possibility that 24-hydroxylated metabolites might have a unique positive role in bone. Subsequent genetic evidence showed that the bone lesion disappeared when VDR signalling was also removed in a CYP24A1/VDR double-null context, supporting excessive calcitriol-VDR activity as a major explanation. Other work discussed in the review suggested that some 24-hydroxylated metabolites might influence fracture repair, but a specific receptor and signalling pathway had not been established.
The most secure conclusion is therefore that CYP24A1 is essential for normal catabolic control of vitamin D metabolites, while possible independent biological actions of individual downstream metabolites remain a separate and less settled question.
Human CYP24A1 loss-of-function produces the opposite biochemical problem to CYP27B1 loss
Human genetics reinforces the contrast between activation and degradation. Loss-of-function variants in CYP24A1 have been identified in idiopathic infantile hypercalcaemia and related hypercalcaemic phenotypes. The underlying direction is excessive persistence of vitamin D metabolites because normal catabolic processing is impaired.
That mechanism is the biochemical opposite of CYP27B1 deficiency. With CYP27B1 loss, the system struggles to create adequate calcitriol even when precursor exists. With CYP24A1 loss, the problem is inadequate removal of vitamin D metabolites after they are available. Both disorders can disturb calcium and phosphate physiology, but they do so from opposite sides of the metabolic balance.
PTH, FGF23 and calcitriol regulate formation and removal in reciprocal directions
The kidney does not regulate CYP27B1 and CYP24A1 independently. PTH generally promotes calcitriol production by increasing renal CYP27B1 and opposing the catabolic arm. FGF23 pushes the system toward lower active-hormone availability by suppressing activation and promoting catabolic metabolism. Calcitriol itself provides negative feedback: it suppresses further CYP27B1 expression while strongly inducing CYP24A1 through VDR-dependent transcription.
This reciprocal regulation produces a coordinated change in metabolic flux. When physiological demand for calcitriol rises, increasing formation while reducing catabolism amplifies the response. When active hormone is abundant, reducing formation while increasing CYP24A1-mediated metabolism helps bring exposure back down.
The same logic also operates locally, but not necessarily with the same hormonal inputs in every tissue. CYP24A1 is strongly induced by VDR signalling in many target cells, providing a local feedback mechanism that can limit the duration of vitamin D receptor activation.
CYP3A4 provides an additional catabolic route in selected tissues and exposure settings
CYP24A1 is the specialised enzyme at the centre of the major regulated 23/24 oxidation pathways, but vitamin D metabolism is not exclusive to CYP24A1 in every tissue. The review describes CYP3A4-mediated oxidation of vitamin D compounds, particularly in liver and intestine and in contexts where CYP3A4 activity is high or induced.
This alternative pathway has a different physiological emphasis from CYP24A1. CYP3A4 has broad substrate specificity and kinetic characteristics that make it part of a wider xenobiotic and steroid-metabolism system, whereas CYP24A1 is tightly integrated into vitamin D endocrine feedback. The presence of CYP3A4 therefore qualifies an absolute statement that CYP24A1 is the only route of vitamin D catabolism without diminishing CYP24A1’s central specialised role.
What this review establishes and what remains uncertain
Jones and colleagues synthesise evidence from recombinant enzymes, kinetic studies, structural biology, mutagenesis, animal knockouts, human genetic disorders and endocrine physiology. The strength of that approach is breadth: the same enzyme roles are supported from molecular mechanism through whole-organism consequences. The limitation is that the quantitative findings do not come from one unified experiment. Rat mutagenesis ratios, mouse knockout half-lives and human genetic phenotypes must retain their own model boundaries.
The evidence firmly supports CYP27B1 as the key 1α-hydroxylase for calcitriol formation and CYP24A1 as the specialised enzyme driving major 23/24 oxidative catabolic pathways. It also supports reciprocal renal regulation and a strong effect of complete CYP24A1 loss on calcitriol persistence. It does not show that every extra-renal tissue contributes substantially to circulating calcitriol, that CYP24A1 is the only catabolic enzyme everywhere, or that every CYP24A1-derived metabolite is completely inactive.
Those limits make the central physiology clearer rather than weaker. Vitamin D activity is controlled by a dynamic balance: CYP27B1 creates active hormone, CYP24A1 progressively reduces precursor and active-hormone availability, tissue context determines how those reactions are regulated, and alternative oxidative routes can contribute in particular settings.
Primary source and publication details
Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. Journal of Lipid Research. 2014;55(1):13 to 31. PMID 23564710; PMCID PMC3927478; DOI 10.1194/jlr.R031534.
Read the full Jones, Prosser and Kaufmann paper.
The Study Summary provides a faster route through the same evidence.
Related reading
25-Hydroxyvitamin D3 and 1,25-Dihydroxyvitamin D3 Promote the Differentiation of Human Subcutaneous Preadipocytes
1,25(OH)2D3 inhibits adipogenesis in mouse 3T3-L1 adipocytes, but little is known about its effects or local metabolism in human adipose tissue.
Original paper ↗Read more →Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors
Vitamin D is a precursor for secosteroidal hormones, which demonstrate pleiotropic biological activities, including the regulation of growth and the differentiation of normal and malignant cells.
Original paper ↗Read more →Association between Polymorphism of the Vitamin D Metabolism Gene CYP27B1 and HLA-B27-Associated Uveitis. Is a State of Relative Immunodeficiency Pathogenic in HLA B27-Positive Uveitis?
The aim of this study was to investigate a possible association between the rs703842 A>G polymorphism of the CYP27B1 gene and HLA-B27-associated uveitis.
Original paper ↗Read more →Associations of genetically predicted vitamin D status and deficiency with the risk of carotid artery plaque: a Mendelian randomization study
However, randomized controlled trials have not reported the beneficial effects of vitamin D supplementation on atherosclerotic cardiovascular disease (ASCVD) outcomes.
Original paper ↗Read more →Expression of Vitamin D Receptor (VDR) Positively Correlates with Survival of Urothelial Bladder Cancer Patients
The aim of the present research was to examine whether the expression of the VDR and CYP27B1 in bladder cancer was related to the prognostic markers and disease outcome.
Original paper ↗Read more →Genetic Association between Serum 25-Hydroxyvitamin D Levels and Lung Function in Korean Men and Women: Data from KNHANES 2011 to 2012
We examined the association between five SNPs on DHCR7, GC, CYP2R1, and CYP24A1 along with serum 25-hydroxyvitamin D (25(OH)D) levels and lung function in older Korean men (n = 758) and women (n = 837).
Original paper ↗Read more →Genetic Polymorphism of CYP2R1, CYP27A1, CYP27B1, and Vitamin D Metabolites Plasma Levels in Patients with Cardiovascular Disease: A Pilot Study
Among patients, those with the GT genotype of rs10877012 (CYP27B1) had higher 25(OH)D3 levels compared to other genotypes.
Original paper ↗Read more →High Expression of Antiviral and Vitamin D Pathway Genes Are a Natural Characteristic of a Small Cohort of HIV-1-Exposed Seronegative Individuals
In addition, the expression of TIM-3 on T and NK cells of six HCs after calcidiol and calcitriol (active VitD) treatments was evaluated by flow cytometry.
Original paper ↗Read more →High Vitamin D Concentrations Restore the Ability to Express LL37 by M. tuberculosis-Infected Human Macrophages
This study aimed to evaluate the vitamin D contribution in the expression of VDR and CYP27B1, involved in the conversion of an inactive to an active form of vitamin D in the infected macrophages using M.
Original paper ↗Read more →Lower placental 25-hydroxyvitamin D3 (25(OH)D3) and higher placental CYP27B1 and 25(OH)D3 ratio in preterm birth
Our study concludes that preterm birth showed lower placental 25(OH)D3 status, and higher CYP27B1/25(OH)D3 ratio compared to term pregnancy.
Original paper ↗Read more →Primary Human Osteoblasts in Response to 25-Hydroxyvitamin D3, 1,25-Dihydroxyvitamin D3 and 24R,25-Dihydroxyvitamin D3
Silencing of CYP27B1 resulted in a decline of 1,25(OH)2D3 synthesis, but we observed no significant differences in mRNA levels of differentiation markers in CYP27B1-silenced cells compared to control cells after treatment with 25(OH)D3.
Original paper ↗Read more →Role of Multiple Vitamin D-Related Polymorphisms in Multiple Sclerosis Severity: Preliminary Findings
The aim of this observational study was to evaluate the potential association among vitamin D status, MS severity, and vitamin D-related SNPs, alone or in combination.
Original paper ↗Read more →Sirt1 overexpression improves senescence‐associated pulmonary fibrosis induced by vitamin D deficiency through downregulating IL‐11 transcription
Lungs from young and physiologically aged wild‐type (WT) mice were examined for cell senescence, fibrosis markers, and TGF‐β1/IL‐11/MEK/ERK signaling proteins, and 1,25(OH)2D3 and IL‐11 levels were detected in serum.
Original paper ↗Read more →Transcriptional activity of vitamin D receptor in human periodontal ligament cells is diminished under inflammatory conditions
The aim of this study is to investigate possible alterations of the vitamin D3 activity in hPDLCs under inflammatory conditions.
Original paper ↗Read more →Tuning Adipogenic Differentiation in ADSCs by Metformin and Vitamin D: Involvement of miRNAs
In the present paper, we aimed at evaluating the role of metformin on ADSCs differentiation.
Original paper ↗Read more →Vitamin D and adipose tissue: more than storage
Some of the physiological functions of 1,25(OH)2D3 (1,25-dihydroxycholecalciferol or calcitriol) via its receptor within the adipose tissue have been investigated such as its effect on energy balance, adipogenesis, adipokine, and cytokine secretion.
Original paper ↗Read more →Vitamin D Auto-/Paracrine System Is Involved in Modulation of Glucocorticoid-Induced Changes in Angiogenesis/Bone Remodeling Coupling
Osteoporosis is a devastating side effect of chronic glucocorticoid (GC) treatment.
Original paper ↗Read more →Vitamin D receptor, vitamin D binding protein and CYP27B1 single nucleotide polymorphisms and susceptibility to viral infections in infants
As compared to controls, ΤaqI was more frequent in infants with viral infection compared to controls (p = 0.03, OR 1.96, 95% CI 1.1 to 3.58).
Original paper ↗Read more →The age-related changes of dietary phosphate responsiveness in plasma 1,25-dihydroxyvitamin D levels and renal Cyp27b1 and Cyp24a1 gene expression is associated with renal α-Klotho gene expression in mice
We found that 1,25-dihydroxyvitamin D levels in plasma were significantly lower in the high phosphate group than the low phosphate group for 1 and 2 month-old mice, but not 13 month-old mice.
Original paper ↗Read more →Roles of CYP27B1 and CYP24A1 in activation and inactivation: Study Summary
A concise summary of evidence showing how CYP27B1 activates vitamin D while CYP24A1 regulates its inactivation, metabolism and clearance.SLUG:cyp27b1-cyp24a1-activation-inactivation-study-summary.
Read more →Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1)
Vitamin D enzyme pathways regulate how vitamin D is activated and broken down in the body.
Read more →Original sources
Read the full Jones, Prosser and Kaufmann paper
Read the full Jones, Prosser and Kaufmann paper.
Publication details
Read the full Jones, Prosser and Kaufmann paper.